Colchicine fails to protect against myocardial injury in STEMI when given at the time of reperfusion then continued for 5 days after, according to data from the randomized COVERT-MI. There also is a ...

The newer class of oral anticoagulants that have been supplanting the traditional mainstay warfarin for a variety of indications may be inferior for at least one use — getting rid of left ventricular ...

CHICAGO, IL—Patients who develop thrombus in the left ventricle following myocardial infarction fare equally well when treated with rivaroxaban (Xarelto; Bayer/Janssen) as they do with warfarin, the ...

The effectiveness of rivaroxaban, a direct oral anticoagulant, in resolving acute left ventricular thrombus in patients with ST-segment elevation myocardial infarction (STEMI) was similar to that of ...

A large, modern real-world analysis published today in the Journal of the Society for Cardiovascular Angiography & Interventions (JSCAI), provides vital insights into the safety of novel therapies ...